NCT06327776

New Protein Biomarkers and Technology for Improving Diagnosis and Outcome Prediction in Mild TBI

Nuevos Biomarcadores y Tecnologia Para Una Mejores Reglas de predicción en el Traumatismo craneoncefálico Leve

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 1,000 (estimated)
• Sponsor: Hospital Universitario 12 de Octubre · Academic / Other
• Sex: All
• Age: 15 Years
• Healthy volunteers: Not accepted

Summary

Mild traumatic brain injury(mTBI) is a common cause of consultation to the emergency rooms worldwide and is the most common form of traumatic brain injury. Though classified as mild, as many as 40% of patients suffering mTBI do not make complete recoveries or present persistent symptoms. The present study is intended to determine long term outcome of patients suffering mTBI and to establish new prognostic models with the use of serum and saliva based biomarkers. For this purpose this study will not exclude patients regarding their comorbidities.

Conditions

• Mild Traumatic Brain Injury

Interventions

Type	Name	Description
OTHER	Serum and saliva biomarkers	2x5mL blood samples and saliva samples will be used to determine the performance of different blood based and saliva biomarkers for determining diagnostic management and prognosis in mTBI patients.

Timeline

• Start date: 2022-03-04
• Primary completion: 2025-07-31
• Completion: 2025-12-31
• First posted: 2024-03-25
• Last updated: 2024-03-25

Locations

1 site across 1 country: Spain